Molecular Cancer Research Targeting the PI3-Kinase Pathway in Cancer Chemical and Biological Aspects of Inflammation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nanni, S.
Right arrow Articles by Farsetti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nanni, S.
Right arrow Articles by Farsetti, A.
Molecular Cancer Research 4:79-92 (2006)
© 2006 American Association for Cancer Research


Cancer Genes and Genomics

Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer

Simona Nanni1, Carmen Priolo1,5,6, Annalisa Grasselli1,4, Manuela D'Eletto1, Roberta Merola1, Fabiola Moretti1,5, Michele Gallucci1, Piero De Carli1, Steno Sentinelli1, Anna Maria Cianciulli1, Marcella Mottolese1, Paolo Carlini1, Diego Arcelli3, Mauro Helmer-Citterich3, Carlo Gaetano3, Massimo Loda6, Alfredo Pontecorvi1,2,4, Silvia Bacchetti1, Ada Sacchi1 and Antonella Farsetti1,2,5

1 Departments of Experimental Oncology, Urology, Pathology, Clinical Pathology, and Medical Oncology and 2 Rome Oncogenomic Center, Regina Elena Cancer Institute; 3 Istituto Dermopatico dell'Immacolata; 4 Endocrinology, Catholic University; 5 INeMM, National Research Council, Rome, Italy and 6 Medical Oncology, Dana-Farber Cancer Institute, and Pathology, Brigham & Women's Hospital, Boston, Massachusetts

Requests for reprints: Antonella Farsetti, Molecular Oncogenesis Laboratory, Department of Experimental Oncology, Regina Elena Cancer Institute-Experimental Research Center, Via delle Messi d'Oro 156, 00158 Rome, Italy. Phone: 39-6-5266-2531; Fax: 39-6-41805-26. E-mail: farsetti{at}ifo.it

The histopathologic and molecular heterogeneity of prostate cancer and the limited availability of human tumor tissue make unraveling the mechanisms of prostate carcinogenesis a challenging task. Our goal was to develop an ex vivo model that could be reliably used to define a prognostic signature based on gene expression profiling of cell cultures that maintained the tumor phenotype. To this end, we derived epithelial cultures from tissue explanted from 59 patients undergoing radical prostatectomy or cistoprostatectomy because of prostate benign hyperplasia/prostate cancer or bladder carcinoma. Patient selection criteria were absence of hormonal neoadjuvant treatment before surgery and diagnosis of clinically localized disease. Using this unique experimental material, we analyzed expression of 22,500 transcripts on the Affymetrix Human U133A GeneChip platform (Affymetrix, Inc., High Wycombe, United Kingdom). Cultures from normal/hyperplastic tissues with a prevalent luminal phenotype and from normal prostate epithelial tissue with basal phenotype (PrEC) served as controls. We have established a large number of prostate primary cultures highly enriched in the secretory phenotype. From them, we derived an epithelial-restricted transcriptional signature that (a) differentiated normal from tumor cells and (b) clearly separated cancer-derived lines into two distinct groups, which correlated with indolent or aggressive clinical behavior of the disease. Our findings provide (a) a method to expand human primary prostate carcinoma cells with a luminal phenotype, (b) a powerful experimental model to study primary prostate cancer biology, and (c) a novel means to characterize these tumors from a molecular genetic standpoint for prognostic and/or predictive purposes. (Mol Cancer Res 2006;4(2):79–92)




This article has been cited by other articles:


Home page
FASEB J.Home page
U. Moehren, M. Papaioannou, C. A. Reeb, A. Grasselli, S. Nanni, M. Asim, D. Roell, I. Prade, A. Farsetti, and A. Baniahmad
Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development
FASEB J, April 1, 2008; 22(4): 1258 - 1267.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Cappuzzello, R. Melchionna, A. Mangoni, G. Tripodi, P. Ferrari, L. Torielli, D. Arcelli, M. Helmer-Citterich, G. Bianchi, M. C. Capogrossi, et al.
Role of rat {alpha} adducin in angiogenesis: Null effect of the F316Y polymorphism
Cardiovasc Res, August 1, 2007; 75(3): 608 - 617.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.